The Molecular and Microbial Microenvironments in Chronically Diseased Lungs

To visualize the personalized distributions of pathogens, chemical environments including microbial metabolites, pharmaceuticals, and their metabolic products within and between human lungs afflicted with cystic fibrosis, we generated 3D microbiome and metabolome maps of six explanted lungs from three cystic fibrosis patients. These 3D spatial maps revealed that the chemical environments are variable between patients and within the lungs of each patient. Although the patients’ microbial ecosystems were defined by the dominant pathogen, their chemical diversity was not. Additionally, the chemical diversity between locales in lungs of the same individual sometimes exceeded inter-individual variation. Thus, the chemistry and microbiome of the explanted lungs appear to be not only personalized but also regiospecific. Previously undescribed analogs of microbial quinolones and antibiotic metabolites were also detected. Furthermore, mapping the chemical and microbial distributions allowed visualization of microbial community interactions, such as increased production of quorum sensing quinolones in locations where Pseudomonas was in contact with Staphylococcus and Granulicatella, consistent with in vitro observations of bacteria isolated from these patients. Visualization of microbe-metabolite associations within a host organ in early-stage CF disease in animal models will help elucidate a complex interplay between the presence of a given microbial structure, antibiotics, metabolism of antibiotics, microbial virulence factors, and host responses. Importance Microbial infections are now recognized to be polymicrobial and personalized in nature. A comprehensive analysis and understanding of the factors underlying the polymicrobial and personalized nature of infections remains limited, especially in the context of the host. By visualizing microbiomes and metabolomes of diseased human lungs, we describe how different the chemical environments are between hosts that are dominated by the same pathogen and how community interactions shape the chemical environment, or vice versa. We highlight that three-dimensional organ mapping are hypothesis building tools that allow us to design mechanistic studies aimed at addressing microbial responses to other microbes, the host, and pharmaceutical drugs.

[1]  Quantifying and understanding well-to-well contamination in microbiome research , 2019 .

[2]  Bahar Javdan,et al.  Systematic mapping of drug metabolism by the human gut microbiome , 2019, bioRxiv.

[3]  Rob Knight,et al.  Contamination in Low Microbial Biomass Microbiome Studies: Issues and Recommendations. , 2019, Trends in microbiology.

[4]  Mingxun Wang,et al.  Qiita: rapid, web-enabled microbiome meta-analysis , 2018, Nature Methods.

[5]  Metin Sitti,et al.  Small-scale soft-bodied robot with multimodal locomotion , 2018, Nature.

[6]  H. Batura-Gabryel,et al.  Survival of Patients with Cystic Fibrosis Depending on Mutation Type and Nutritional Status. , 2018, Advances in experimental medicine and biology.

[7]  Theodore Alexandrov,et al.  3D molecular cartography using LC–MS facilitated by Optimus and 'ili software , 2017, Nature Protocols.

[8]  Nuno Bandeira,et al.  Three-Dimensional Microbiome and Metabolome Cartography of a Diseased Human Lung. , 2017, Cell host & microbe.

[9]  Jose A Navas-Molina,et al.  Deblur Rapidly Resolves Single-Nucleotide Community Sequence Patterns , 2017, mSystems.

[10]  Tami D. Lieberman,et al.  Global and local selection acting on the pathogen Stenotrophomonas maltophilia in the human lung , 2017, Nature Communications.

[11]  A. Bowman,et al.  Carbapenemase-Producing Enterobacteriaceae Recovered from the Environment of a Swine Farrow-to-Finish Operation in the United States , 2016, Antimicrobial Agents and Chemotherapy.

[12]  F. Rohwer,et al.  Ecological networking of cystic fibrosis lung infections , 2016, npj Biofilms and Microbiomes.

[13]  Stephan Harbarth,et al.  Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? , 2016, PLoS medicine.

[14]  Barbara A. Bailey,et al.  Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease , 2014, The ISME Journal.

[15]  Kristian Fog Nielsen,et al.  Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking , 2016, Nature Biotechnology.

[16]  H. Nair,et al.  Global disease burden due to antibiotic resistance – state of the evidence , 2016, Journal of global health.

[17]  Blair J. Rossetti,et al.  Biogeography of a human oral microbiome at the micron scale , 2016, Proceedings of the National Academy of Sciences.

[18]  P. Dorrestein,et al.  Evolution of metabolic divergence in Pseudomonas aeruginosa during long-term infection facilitates a proto-cooperative interspecies interaction , 2015, The ISME Journal.

[19]  Barbara A. Bailey,et al.  Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome , 2015, The ISME Journal.

[20]  J. Lipuma,et al.  Cystic fibrosis lung microbiome: Opportunities to reconsider management of airway infection , 2015, Pediatric pulmonology.

[21]  J. Kitzman,et al.  Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. , 2015, Cell host & microbe.

[22]  Kazuo Awai,et al.  Ultra-High-Resolution Computed Tomography of the Lung: Image Quality of a Prototype Scanner , 2015, PloS one.

[23]  J. Curtis,et al.  Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography. , 2015, Annals of the American Thoracic Society.

[24]  S. Donaldson,et al.  Lung microbiota across age and disease stage in cystic fibrosis , 2015, Scientific Reports.

[25]  C. L. Ventola The antibiotic resistance crisis: part 1: causes and threats. , 2015, P & T : a peer-reviewed journal for formulary management.

[26]  R. Brant,et al.  Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years' experience. , 2015, Annals of the American Thoracic Society.

[27]  D. Bumann Heterogeneous host-pathogen encounters: act locally, think globally. , 2015, Cell host & microbe.

[28]  Laura J Shallcross,et al.  Antibiotic overuse: a key driver of antimicrobial resistance. , 2014, The British journal of general practice : the journal of the Royal College of General Practitioners.

[29]  L. T. Angenent,et al.  Metabolite transfer with the fermentation product 2,3-butanediol enhances virulence by Pseudomonas aeruginosa , 2014, The ISME Journal.

[30]  Barbara A. Bailey,et al.  The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography. , 2014, American journal of respiratory and critical care medicine.

[31]  K. Rumbaugh,et al.  Bacterial fight-and-flight responses enhance virulence in a polymicrobial infection , 2014, Proceedings of the National Academy of Sciences.

[32]  H. Goossens,et al.  Antibiotic resistance—the need for global solutions , 2013, BDJ.

[33]  Rob Knight,et al.  EMPeror: a tool for visualizing high-throughput microbial community data , 2013, GigaScience.

[34]  S. Dowd,et al.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota , 2012, Proceedings of the National Academy of Sciences.

[35]  Nuno Bandeira,et al.  Mass spectral molecular networking of living microbial colonies , 2012, Proceedings of the National Academy of Sciences.

[36]  Forest Rohwer,et al.  Spatial distribution of microbial communities in the cystic fibrosis lung , 2011, The ISME Journal.

[37]  M. Pirmohamed,et al.  Mass Spectrometric Characterization of Circulating and Functional Antigens Derived from Piperacillin in Patients with Cystic Fibrosis , 2011, The Journal of Immunology.

[38]  Jessica L. Mark Welch,et al.  Systems-level analysis of microbial community organization through combinatorial labeling and spectral imaging , 2011, Proceedings of the National Academy of Sciences.

[39]  P. Marsh,et al.  The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[40]  Robert C. Edgar,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2001 .

[41]  Matej Oresic,et al.  MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data , 2010, BMC Bioinformatics.

[42]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[43]  R. Knight,et al.  Quantitative and Qualitative β Diversity Measures Lead to Different Insights into Factors That Structure Microbial Communities , 2007, Applied and Environmental Microbiology.

[44]  Carmen Buchrieser,et al.  Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells , 2006, Science.

[45]  H. Senn,et al.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.

[46]  R. Knight,et al.  UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.

[47]  L. Rahme,et al.  Electrospray/mass spectrometric identification and analysis of 4-hydroxy-2-alkylquinolines (HAQs) produced by Pseudomonas aeruginosa , 2004, Journal of the American Society for Mass Spectrometry.

[48]  George M. Hilliard,et al.  Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. , 2002, Advanced drug delivery reviews.

[49]  A. Wade,et al.  A model for predicting life expectancy of children with cystic fibrosis. , 2000, The European respiratory journal.